Jean-David Fumet
Inserm · 133 works · 3,034 citations · h-index 23
Top works
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
- Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
- Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
- Antibiotic Use Does Not Appear to Influence Response to Nivolumab
- MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
- Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
- Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages
- Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
- Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
- First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
- Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
- Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
- Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort
- Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
- Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
- Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
- Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
- Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors
- Targeting BRAF and RAS in Colorectal Cancer